Search results for "Survival"

Staging small cell lung cancer: Veterans Administration Lung Study Group versus International Association for the Study of Lung Cancer--what limits l…

2002

Small cell lung cancer (SCLC) is usually classified into a two-stage system, limited (LD) and extensive disease (ED). However, the criteria for these two categories remain controversial. The widely used Veterans Administration Lung Study Group (VALG) definition of LD includes patients with primary tumor and nodal involvement limited to one hemithorax. In contrast, the International Association for the Study of Lung Cancer (IASLC) recommends that LD should additionally include all patients without distant metastasis. As a consequence, since treatment modalities for LD and ED could be different, individual clinical outcome of SCLC patients may be influenced by the staging system chosen. Among…

165P Baseline circulating myeloid-derived suppressor cells correlate with neutrophil-to-lymphocyte ratio and overall survival in advanced non-small c…

2021

P-147PLASMA PLATELET FACTOR 4 AS PREDICTOR OF ANGIOGENIC ACTIVITY: DIAGNOSTIC AND PROGNOSTIC TOOL FOR EARLY STAGE NON-SMALL CELL LUNG CANCER

2013

Outcomes of Patients With Advanced NSCLC From the Intergroupe Francophone de Cancérologie Thoracique Biomarkers France Study by KRAS Mutation Subtypes

2020

Abstract Introduction KRAS mutations are detected in 20% to 30% of NSCLC. However, KRAS mutation subtypes may differently influence the outcome of patients with advanced NSCLC. Methods In the Biomarkers France study, 4894 KRAS mutations (26.2%) were detected in 4634 patients from the 17,664 enrolled patients with NSCLC. Survival and treatment data on noncurative stage III to IV NSCLC were available for 901 patients. First- and second-line treatment effects on progression-free survival and overall survival were analyzed according to the KRAS mutations subtype. Results Over 95% of patients with KRAS mutation were smokers or former smokers who were white (99.5%), presenting with adenocarcinoma…

Outcomes of Donor-Recipient Gender Mismatched Lung Transplantation in the Eurotransplant Area

2019

Purpose An effect of donor-recipient gender mismatching on long-term survival outcomes following organ transplantation has been postulated but remains controversial. We aimed to investigate the influence of gender mismatches on long-term survival after lung transplantation in the Eurotransplant area. Methods In this retrospective, multicentre study in the Eurotransplant area, all lung transplants performed from DBD lungs in the period from 01.01.2000 until 31.12.2015 were included. A total of 7688 lung transplant recipients (≥ 14 years old) for long-term survival and the effect of gender mismatches (Kaplan-Meier, multivariate regression). Results More men (4079; 52 %) were transplanted comp…

221 Better Event-Free Survival in Ambulatory Heart Transplant (HTx) Candidates Who Are Physically Active and in Good Mood

2012

(pre-Group1 89.6 6.1 x pre-Group2 89.3 6.9, p 0.8; 1yr97.6 1.1 x 97.1 1.5, p 0.3; 2yr96.8 2.3 x 97.0 1.1,p 0.9,in %); MIP (pre64.0 23.9 x 65.5 24.2, p 0.8; 1yr94.9 25.2 x 98.5 15.6, p 0.7; 2yr93.4 26.6 x 101.3 12.6, p 0.7) and MEP (pre-92 29.1 x 86.5 27.1, p 0.5; 1yr 99.2 28.5 x 104.9 16.4,p 0.9; 2yr 103.14 25 x 105.6 16.4, p 0.7,in cmH2O) and 6MWT (pre-428 137.4 x 411.2 113.9, p 0.5; 1yr 629.2 91.26 x 659.2 93.5, p 0.3; 2yr 645.9 91.5 x 686.6 98.6, p 0.2,in meters). Conclusions: Our findings indicate that unsupervised rehabilitation may represent an alternative in the management of post lung transplant patients.

A single-institution retrospective analysis of metachronous and synchronous metastatic bronchial neuroendocrine tumors

2018

Background: Broncho-pulmonary neuroendocrine tumors (bpNETs) are rare malignancies and there is no consensus on therapeutical management of metastatic disease and follow-up after radical resection. Methods: Clinical records of patients with a cytological or histological diagnosis of bpNETs and distant metastases (metachronous or synchronous), evaluated at the European Institute of Oncology between 1997 and 2014, were retrospectively analyzed. Data on patient demographics, pathology, imaging exams, surgical and non-surgical treatments were collected. P value descriptive data, uni- and multi-variate survival analysis were generated for all variables. Results: With a median follow-up of 53 [9–…

Estimation and prognosis value of elderly colorectal cancer patients' quality of life. : A population-based study

2014

Colorectal cancer is one of the most common malignancies in France and predominantly affects older patients. Few studies evaluating baseline quality of life of those patients, its short term evolution and its prognosis value on patients' survival have been performed in the context of a population-based study. This work is based on a prospective longitudinal cohort study performed by the Burgundy Digestive Cancer Registry. All patients aged 65 and over, diagnosed with a new colorectal cancer and registered by the Registry between 2003 and 2005 were eligible. Among the 401 eligible patients, 246 fulfilled at least one questionnaire. Non-respondents were older and diagnosed with a more advance…

Impact de l'âge dans le cancer du sein : du diagnostic à la qualité de vie des patientes

2014

Numerous studies have shown that older women with breast cancer are undertreated in comparison with the youngest. Although several reports suggest strong socio-economic and geographic inequalities in the disease stage at diagnosis and in quality of life in breast cancer patients, the effects of these factors according to age are largely unknown in France. The objectives of this work were to determine the impact of socio-economic and geographic disparities on disease stage in breast cancer patients according to age, to describe treatments and relative survival factors in breast cancer patients according to age, and to identify age-related socioeconomic and clinical determinants of quality of…

Novel Cancer Chemotherapy Hits by Molecular Topology: Dual Akt and Beta-Catenin Inhibitors

2015

Background and purposeColorectal and prostate cancers are two of the most common types and cause of a high rate of deaths worldwide. Therefore, any strategy to stop or at least slacken the development and progression of malignant cells is an important therapeutic choice. The aim of the present work is the identification of novel cancer chemotherapy agents. Nowadays, many different drug discovery approaches are available, but this paper focuses on Molecular Topology, which has already demonstrated its extraordinary efficacy in this field, particularly in the identification of new hit and lead compounds against cancer. This methodology uses the graph theoretical formalism to numerically chara…